F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Menius, E D
Donfield, S M
Gomperts, E D
Nelson, G W
Shapiro, A D
Winkler, C A
Onundarson, Pall T
MetadataShow full item record
CitationHaemophilia 2013, 19(1):113-8
AbstractAncestral background, specifically African descent, confers higher risk for development of inhibitory antibodies to factor VIII (FVIII) in haemophilia A. It has been suggested that differences in the distribution of FVIII gene (F8) haplotypes, and mismatch between endogenous F8 haplotypes and those comprising products used for treatment could contribute to risk. Data from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort were used to determine the association between F8 haplotype 3 (H3) vs. haplotypes 1 and 2 (H1 + H2) and inhibitor risk among individuals of genetically determined African descent. Other variables known to affect inhibitor risk including type of F8 mutation and human leucocyte antigen (HLA) were included in the analysis. A second research question regarding risk related to mismatch in endogenous F8 haplotype and recombinant FVIII products used for treatment was addressed. Haplotype 3 was associated with higher inhibitor risk among those genetically identified (N = 49) as of African ancestry, but the association did not remain significant after adjustment for F8 mutation type and the HLA variables. Among subjects of all racial ancestries enrolled in HIGS who reported early use of recombinant products (N = 223), mismatch in endogenous haplotype and the FVIII proteins constituting the products used did not confer greater risk for inhibitor development. Haplotype 3 was not an independent predictor of inhibitor risk. Furthermore, our findings did not support a higher risk of inhibitors in the presence of a haplotype mismatch between the FVIII molecule infused and that of the individual.
DescriptionTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to Haemophilia : the official journal of the World Federation of Hemophilia
- Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients.
- Authors: Lochan A, Macaulay S, Chen WC, Mahlangu JN, Krause A
- Issue date: 2014 Sep
- A large-scale computational study of inhibitor risk in non-severe haemophilia A.
- Authors: Shepherd AJ, Skelton S, Sansom CE, Gomez K, Moss DS, Hart DP
- Issue date: 2015 Feb
- Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
- Authors: Gouw SC, Van Der Bom JG, Van Den Berg HM, Zewald RA, Ploos Van Amstel JK, Mauser-Bunschoten EP
- Issue date: 2011 Mar
- F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.
- Authors: Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W, Hemophilia Inhibitor Research Study Investigators.
- Issue date: 2012 May
- Immune response to FVIII in hemophilia A: an overview of risk factors.
- Authors: Ghosh K, Shetty S
- Issue date: 2009 Oct